Compare FRAF & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | ALXO |
|---|---|---|
| Founded | 1906 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.8M | 240.8M |
| IPO Year | 1995 | 2020 |
| Metric | FRAF | ALXO |
|---|---|---|
| Price | $58.45 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 29.7K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 88.84 | 26.36 |
| EPS | ★ 4.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.44 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $12.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.44 | $0.41 |
| 52 Week High | $60.00 | $2.66 |
| Indicator | FRAF | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 60.25 | 60.00 |
| Support Level | $45.02 | $1.99 |
| Resistance Level | $60.00 | $2.30 |
| Average True Range (ATR) | 1.90 | 0.16 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 69.98 | 95.76 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.